Plain-English translation of NCT05824923 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new procedure called pulmonary artery denervation (PADN), which uses radiofrequency energy to block nerves in blood vessels of the lungs. The procedure is being tested in people who have heart failure and also have abnormally high pressure in their lung blood vessels, even though they are already taking heart failure medications. Researchers want to see if this procedure, when added to standard heart failure treatment, can improve how patients feel and function.
Many people with heart failure develop high pressure in their lung blood vessels, which makes their symptoms worse and limits their activities. Current medications help, but not enough for some patients. This trial exists to see whether blocking these nerves can reduce lung pressure and improve quality of life for people who aren't getting enough relief from medications alone.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this trial, you will be randomly assigned to either receive the pulmonary artery denervation procedure plus your regular heart failure medications, or to continue with heart failure medications alone. The procedure itself is done through a catheter (a thin tube) inserted through a blood vessel, similar to a heart catheterization you may have had. You will need to visit the study center multiple times over 3 years for follow-up appointments, heart tests, and blood work to monitor how you are doing.
AI-generated summary from trial data ยท Jun 16, 2026 ยท Not medical advice
China